Talon CEO: Marqibo US FDA win provides hope for ‘hopeless’ Ph-ALL patients
This article was originally published in Scrip
Executive Summary
After winning over two of the most skeptical members of the US FDA's Oncologic Drugs Advisory Committee (ODAC) at a 21 March meeting – panel chairman Dr Wyndham Wilson, chief of lymphoma therapeutics in the Metabolism Branch at the US National Cancer Institute (NCI) and Dr Mikkael Sekeres, an associate professor of medicine at the Cleveland Clinic in Ohio – it perhaps should have come as no surprise that Talon Therapeutics gained the agency's OK on 9 August for Marqibo (vincristine sulfate liposomes injection).